Bristol Myers Squibb has entered a global agreement with Evinova to deploy AI-powered clinical development tools across its worldwide pipeline. The Bristol Myers Evinova partnership is designed to improve trial efficiency, reduce costs and support better decision-making throughout drug development.
Under the agreement, BMS will roll out Evinova’s “cost optimizer” module, part of the study designer solution developed by the Swiss-based platform. Evinova, which was launched by AstraZeneca in 2023, focuses on applying AI and digital tools to optimize clinical trial design and execution. The collaboration aims to identify productivity opportunities and enable more efficient trial designs across BMS’ global portfolio.
BMS Chief Medical Officer and head of development Cristian Massacesi said the collaboration reflects the need to rethink traditional drug development models.
“For years, developing medicines has taken too long, cost too much money and mostly resulted in failure,” he said via release. “Digital tools and AI can help us overcome these limitations and lay the foundation for better health outcomes for countless individuals in the years to come.”
The Bristol Myers Evinova partnership comes as BMS prepares for revenue pressure from its legacy medicines, including Eliquis, Revlimid and Pomalyst. Sales from that portfolio declined 16% to $21.7 billion last year.
At the same time, products in BMS’ growth portfolio represented more than half of the company’s performance in 2025, generating $26.4 billion of total revenue of $48.2 billion. Newer medicines such as melanoma treatment Opdualag, CAR-T therapy Breyanzi and heart drug Camzyos each posted blockbuster performances last year. Blood disorder therapy Reblozyl generated more than $2 billion in revenue.
These newer treatments helped BMS deliver fourth-quarter revenues of $12.5 billion, 2% above analysts’ expectations. However, overall company sales saw a slight decline from $48.3 billion in 2024.
Separately, BMS also signed an $850 million solid tumor partnership with T-cell engager biotech Janux, reinforcing its strategy to strengthen its pipeline as legacy products face erosion.
